HRP20100674T1 - Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka - Google Patents
Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka Download PDFInfo
- Publication number
- HRP20100674T1 HRP20100674T1 HR20100674T HRP20100674T HRP20100674T1 HR P20100674 T1 HRP20100674 T1 HR P20100674T1 HR 20100674 T HR20100674 T HR 20100674T HR P20100674 T HRP20100674 T HR P20100674T HR P20100674 T1 HRP20100674 T1 HR P20100674T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- preparation according
- proportion
- active agent
- pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 3
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 201000011510 cancer Diseases 0.000 title claims 2
- GWEHVDNNLFDJLR-UHFFFAOYSA-N 1,3-diphenylurea Chemical class C=1C=CC=CC=1NC(=O)NC1=CC=CC=C1 GWEHVDNNLFDJLR-UHFFFAOYSA-N 0.000 title 1
- 239000013543 active substance Substances 0.000 claims abstract 10
- 239000000203 mixture Substances 0.000 claims abstract 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- 239000000314 lubricant Substances 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000007908 dry granulation Methods 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 229940127084 other anti-cancer agent Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- JODIEZIJHKKWKN-UHFFFAOYSA-N 3-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide Chemical compound CNC(=O)C1=NC=CC=C1OC(C=C1)=CC=C1NC(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 JODIEZIJHKKWKN-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Farmaceutski pripravak naznacen time da je tableta koja sadrzi p-toluensulfonsku kiselu sol 4{4-[3-(4-kloro-3-trifluorometilfenil)-ureido]-fenoksi}-piridin-2-karboksilne kiselina metil amida kao aktivno sredstvo koje ima udio od najmanje 55% tezinski pripravka. Patent sadrzi jos 19 patentnih zahtjeva.
Claims (20)
1. Farmaceutski pripravak naznačen time da je tableta koja sadrži p-toluensulfonsku kiselu sol 4{4-[3-(4-kloro-3-trifluorometilfenil)-ureido]-fenoksi}-piridin-2-karboksilne kiselina metil amida kao aktivno sredstvo koje ima udio od najmanje 55% težinski pripravka.
2. Farmaceutski pripravak prema zahtjevu 1 naznačen time da aktivno sredstvo ima udio od najmanje 75% težinski pripravka.
3. Farmaceutski pripravak prema zahtjevu 1 naznačen time da punilo ima udio od 3 do 20 %, sredstvo za raspadanje ima udio od 5 do 12 %, vezivo ima udio od 0.5 do 8 %, lubrikant ima udio od 0.2 do 0.8 % i surfaktant ima udio od 0.1 do 2 % težinski pripravka.
4. Farmaceutski pripravak prema zahtjevu 2 naznačen time da je mikrokristalinična celuloza kao punilo u udjelu od 3 do 20 %, kroskarmeloza natrij kao sredstvo za raspadanje u udjelu od 5 do 12 %, hipromelozu kao vezivo u udjelu od 0.5 do 8 %, magnezijev stearat kao lubrikant u udjelu od 0.2 do 8 % i natrijev lauril sulfat kao surfaktant u udjelu od 0.1 do 2 % težinski pripravka.
5. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 4 naznačen time da je tableta sa neposrednim otpuštanjem.
6. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 5 naznačen time da je aktivno sredstvo mikronizirano.
7. Farmaceutski pripravak prema zahtjevu 6 naznačen time da mikronizirani oblik ima veličinu čestica od 0.5 do 10 µm.
8. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 7 naznačen time da sadrži vodu u količini manjoj od ili jednakoj 6 % težinski pripravka.
9. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 8 naznačen time da ima čvrstoću od više od 80 N.
10. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 9 naznačen time da je ovalna tableta sa najdužom dimenzijom manjom od ili jednakom 25 mm.
11. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 9 naznačen time da je okrugla tableta sa promjerom manjim od ili jednakim 13 mm.
12. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 11 naznačen time da količina aktivnog sredstva je od 54 mg do 1096 mg.
13. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 12 naznačen time da je za oralnu primjenu.
14. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 13 naznačen time da je u kombinaciji s jednim ili više citotoksičnih sredstava, inhibitora transdukcije signala ili s drugim anti-karcinomskim sredstvima ili terapijama, kao i sa smjesama i njihovim kombinacijama.
15. Postupak proizvodnje farmaceutskog pripravka prema bilo kojem od zahtjeva 1 do 14 naznačen time da je aktivno sredstvo pomiješano s najmanje jednom farmaceutski prihvatljivom pomoćnom tvari.
16. Postupak prema zahtjevu 15 naznačen time da:
a) aktivno sredstvo i barem jedna farmaceutski prihvatljiva pomoćna tvar su mokro granulirane,
b) granulat je pomiješan sa lubrikantom i po izboru s jednom ili više dodatnih farmaceutski prihvatljivih pomoćnih tvari,
c) granulat je nakon miješanja podijeljen na pojedinačne jedinice,
d) te se produkt iz koraka c) po potrebi prevlači sa jednom ili više dodatnih farmaceutski prihvatljivih pomoćnih tvari.
17. Postupak prema bilo kojem od zahtjeva 15 ili 16 naznačen time da se produkt iz koraka c) prevlači sa jednom ili više dodatnih farmaceutski prihvatljivih pomoćnih tvari.
18. Postupak prema zahtjevu 15 naznačen time da su aktivno sredstvo i barem jedna farmaceutski prihvatljiva pomoćna tvar pomiješane bez granulacije i direktno komprimirane u tablete.
19. Postupak prema zahtjevu 15 naznačen time da su aktivno sredstvo samo ili aktivno sredstvo i barem jedna farmaceutski prihvatljiva pomoćna tvar tretirane postupkom suhe granulacije i zatim komprimirane u tablete.
20. Uporaba farmaceutskog pripravka prema bilo kojem od zahtjeva 1 do 14 naznačena time da je za proizvodnju lijeka za liječenje hiper-proliferativnih poremećaja kod sisavaca, uključujući rak.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65882705P | 2005-03-07 | 2005-03-07 | |
PCT/EP2006/001574 WO2006094626A1 (en) | 2005-03-07 | 2006-02-22 | Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100674T1 true HRP20100674T1 (hr) | 2011-01-31 |
Family
ID=36507604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100674T HRP20100674T1 (hr) | 2005-03-07 | 2010-12-06 | Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka |
Country Status (38)
Country | Link |
---|---|
US (2) | US9737488B2 (hr) |
EP (1) | EP1868579B1 (hr) |
JP (1) | JP5304241B2 (hr) |
KR (1) | KR101335932B1 (hr) |
CN (2) | CN104688697A (hr) |
AR (1) | AR054234A1 (hr) |
AT (1) | ATE482693T1 (hr) |
AU (1) | AU2006222365B2 (hr) |
BR (1) | BRPI0608840B8 (hr) |
CA (1) | CA2601955C (hr) |
CR (1) | CR9348A (hr) |
CU (1) | CU23821A3 (hr) |
CY (1) | CY1111065T1 (hr) |
DE (1) | DE602006017188D1 (hr) |
DK (1) | DK1868579T3 (hr) |
DO (1) | DOP2006000057A (hr) |
ES (1) | ES2351612T3 (hr) |
GT (1) | GT200600096A (hr) |
HK (2) | HK1118019A1 (hr) |
HN (1) | HN2006009702A (hr) |
HR (1) | HRP20100674T1 (hr) |
IL (1) | IL185517A (hr) |
MA (1) | MA29378B1 (hr) |
MX (1) | MX2007010856A (hr) |
MY (1) | MY162319A (hr) |
NO (1) | NO343834B1 (hr) |
NZ (1) | NZ561178A (hr) |
PE (1) | PE20061345A1 (hr) |
PL (1) | PL1868579T3 (hr) |
PT (1) | PT1868579E (hr) |
SG (1) | SG160364A1 (hr) |
SI (1) | SI1868579T1 (hr) |
TN (1) | TNSN07341A1 (hr) |
TW (1) | TWI324928B (hr) |
UA (1) | UA93673C2 (hr) |
UY (1) | UY29410A1 (hr) |
WO (1) | WO2006094626A1 (hr) |
ZA (1) | ZA200707638B (hr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
JP4636486B2 (ja) | 2002-02-11 | 2011-02-23 | バイエル、ファーマシューテイカルズ、コーポレイション | 脈管形成阻害活性を有するアリール尿素 |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
DK1636585T3 (da) | 2003-05-20 | 2008-05-26 | Bayer Pharmaceuticals Corp | Diarylurinstoffer med kinasehæmmende aktivitet |
BRPI0412219B8 (pt) | 2003-07-23 | 2021-07-27 | Bayer Healthcare Llc | compostos ômega-carboxi aril difenil uréia fluoro substituídos e composições farmacêuticas compreendendo os referidos compostos |
US8877933B2 (en) * | 2004-09-29 | 2014-11-04 | Bayer Intellectual Property Gmbh | Thermodynamically stable form of a tosylate salt |
CN104688697A (zh) | 2005-03-07 | 2015-06-10 | 拜尔健康护理有限责任公司 | 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物 |
JP2009513707A (ja) * | 2005-10-31 | 2009-04-02 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | ジアリールウレア及び併用剤 |
TW200820991A (en) * | 2006-07-10 | 2008-05-16 | Elan Pharma Int Ltd | Nanoparticulate sorafenib formulations |
AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
JP5885012B2 (ja) | 2007-01-19 | 2016-03-15 | バイエル・ヘルスケア・エルエルシーBayer HealthCareLLC | Kit阻害剤に対して獲得した抵抗性を有する癌の処置 |
WO2009106825A1 (en) * | 2008-02-27 | 2009-09-03 | Cipla Limited | Polymorphs of sorafenib and salts thereof |
CN102099018B (zh) | 2008-05-15 | 2016-01-13 | 细胞基因公司 | 胞苷类似物的口服制剂和其使用方法 |
WO2010142678A2 (en) * | 2009-06-12 | 2010-12-16 | Ratiopharm Gmbh | Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide |
US8618305B2 (en) | 2010-01-29 | 2013-12-31 | Ranbaxy Laboratories Limited | Sorafenib dimethyl sulphoxide solvate |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
EP2621486A1 (en) | 2010-10-01 | 2013-08-07 | Bayer Intellectual Property GmbH | Substituted n-(2-arylamino)aryl sulfonamide-containing combinations |
EP2559431A1 (en) | 2011-08-17 | 2013-02-20 | Ratiopharm GmbH | Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide |
WO2013110644A1 (en) | 2012-01-23 | 2013-08-01 | Sandoz Ag | Pharmaceutical composition containing crystalline sorafenib tosylate |
CN104736178A (zh) | 2012-06-04 | 2015-06-24 | 药品循环公司 | 布鲁顿酪氨酸激酶抑制剂的晶形 |
SG11201700849XA (en) | 2014-08-07 | 2017-03-30 | Pharmacyclics Llc | Novel formulations of a bruton's tyrosine kinase inhibitor |
JP7149076B2 (ja) | 2015-03-03 | 2022-10-06 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤の薬学的製剤 |
US11324829B2 (en) * | 2016-03-14 | 2022-05-10 | Santen Pharmaceutical Co., Ltd. | Antiseptic agent comprising meglumine or salt thereof |
CN106344530B (zh) * | 2016-09-30 | 2019-03-19 | 京津冀联创药物研究(北京)有限公司 | 一种索拉非尼组合物及其制备方法 |
CN111315368A (zh) | 2017-05-26 | 2020-06-19 | 布鲁因生物科学公司 | 化学栓塞剂 |
US11179322B2 (en) | 2018-07-10 | 2021-11-23 | Novocure Gmbh | Methods and compositions for treating tumors with TTFields and sorafenib |
WO2018211336A2 (en) * | 2018-09-07 | 2018-11-22 | Alvogen Malta Operations (Row) Ltd | Solid dosage form containing sorafenib tosylate |
CR20210287A (es) | 2018-11-01 | 2022-02-15 | Syros Pharmaceuticals Inc | Inhibidores de cinasa 7 dependiente de ciclina (cdk7) |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3125359A (en) * | 1964-03-17 | Push-pull breakaway coupling | ||
NL121140C (hr) * | 1961-11-08 | |||
AU594098B2 (en) | 1985-12-11 | 1990-03-01 | Ishihara Sangyo Kaisha Ltd. | N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation |
DK607188A (da) | 1987-11-02 | 1989-06-22 | Merck & Co Inc | Tablet indeholdende en phthalazineddikesyreforbindelse |
US5547966A (en) * | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
US6106865A (en) * | 1995-01-09 | 2000-08-22 | Edward Mendell Co., Inc. | Pharmaceutical excipient having improved compressibility |
GB9501127D0 (en) | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
US5773459A (en) | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
WO1997004765A1 (en) | 1995-07-25 | 1997-02-13 | Smithkline Beecham Corporation | INHIBITION OF CoA-INDEPENDENT TRANSACYLASE AND APOPTOSIS |
EP0902782A1 (en) | 1996-04-23 | 1999-03-24 | Vertex Pharmaceuticals Incorporated | Urea derivatives as inhibitors of impdh enzyme |
CA2291065C (en) | 1997-05-23 | 2010-02-09 | Bayer Corporation | Raf kinase inhibitors |
US6187799B1 (en) * | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
DE69826695T2 (de) | 1997-05-23 | 2006-02-02 | Bayer Pharmaceuticals Corp., West Haven | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen |
IL136773A0 (en) | 1997-12-22 | 2001-06-14 | Bayer Ag | Inhibition of raf kinase aryl and heteroaryl substituted heterocyclic ureas |
US20080300281A1 (en) * | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
US20070244120A1 (en) * | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
DE69829412T2 (de) | 1997-12-22 | 2005-07-28 | Bayer Pharmaceuticals Corp., West Haven | Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen |
ES2154252T3 (es) | 1997-12-22 | 2005-12-01 | Bayer Pharmaceuticals Corp. | Inhibicion de quinasa p38 utilizando difenil-ureas simetricas y asimetricas. |
US7329670B1 (en) * | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
US7517880B2 (en) * | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
IL136738A0 (en) | 1997-12-22 | 2001-06-14 | Bayer Ag | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
ES2153340T3 (es) | 1997-12-22 | 2006-02-01 | Bayer Pharmaceuticals Corp. | Inhibicion de la quinasa raf utilizando ureas heterociclicas sustituidas. |
PT1043995E (pt) | 1997-12-22 | 2007-01-31 | Bayer Pharmaceuticals Corp | Inibição da actividade de p38-quinase utilização de ureias heterocíclicas substituídas com arilo ou heteroarilo |
US20010014352A1 (en) | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
US20030087849A1 (en) | 2001-07-03 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of HKR1 expression |
US6117451A (en) | 1998-08-25 | 2000-09-12 | Pharmalogix, Inc. | Direct compression metformin hydrochloride tablets |
US20080269265A1 (en) * | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
ME00275B (me) * | 1999-01-13 | 2011-02-10 | Bayer Corp | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US20020065296A1 (en) * | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
EP1158985B1 (en) * | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
PL204856B1 (pl) * | 1999-01-22 | 2010-02-26 | Kirin Pharma Kk | Pochodne chinoliny lub chinazoliny, jej zastosowanie i kompozycja farmaceutyczna |
JP2004506680A (ja) * | 2000-08-18 | 2004-03-04 | ファルマシア・コーポレーション | シクロオキシゲナーゼ−2阻害剤の迅速崩壊経口製剤 |
US7235576B1 (en) * | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
DK1370552T3 (da) | 2001-03-23 | 2007-05-07 | Bayer Pharmaceuticals Corp | Rho-kinase-inhibitorer |
US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
US20030207914A1 (en) * | 2001-04-20 | 2003-11-06 | Bayer Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
ATE355272T1 (de) | 2001-04-20 | 2006-03-15 | Bayer Pharmaceuticals Corp | Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffe |
DE60216139T3 (de) * | 2001-12-03 | 2018-11-15 | Bayer Healthcare Llc | Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen |
JP2005526008A (ja) * | 2001-12-04 | 2005-09-02 | オニックス ファーマシューティカルズ,インコーポレイティド | 癌を処置するためのraf−mek−erk経路インヒビター |
US20030207872A1 (en) * | 2002-01-11 | 2003-11-06 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
WO2003068223A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
US10653684B2 (en) | 2002-02-11 | 2020-05-19 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
DK1580188T3 (da) | 2002-02-11 | 2012-02-06 | Bayer Healthcare Llc | Forbindelser af arylurea som kinaseinhibitorer |
AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
JP4636486B2 (ja) | 2002-02-11 | 2011-02-23 | バイエル、ファーマシューテイカルズ、コーポレイション | 脈管形成阻害活性を有するアリール尿素 |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
WO2003101444A1 (en) * | 2002-05-29 | 2003-12-11 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
CA2516627A1 (en) | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Substituted pyridine derivatives useful in the treatment of cancer and other disorders |
WO2004078748A2 (en) | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders |
US7557129B2 (en) * | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
EP1599466B1 (en) | 2003-02-28 | 2010-11-24 | Bayer HealthCare LLC | 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders |
US6896863B2 (en) * | 2003-04-01 | 2005-05-24 | E. I. Du Pont De Nemours And Company | Sodium cyanide process |
DK1636585T3 (da) | 2003-05-20 | 2008-05-26 | Bayer Pharmaceuticals Corp | Diarylurinstoffer med kinasehæmmende aktivitet |
US20060234931A1 (en) | 2003-07-17 | 2006-10-19 | Biggs William H Iii | Treatment of diseases with kinase inhibitors |
BRPI0412219B8 (pt) * | 2003-07-23 | 2021-07-27 | Bayer Healthcare Llc | compostos ômega-carboxi aril difenil uréia fluoro substituídos e composições farmacêuticas compreendendo os referidos compostos |
JP2007505938A (ja) * | 2003-09-23 | 2007-03-15 | ノバルティス アクチエンゲゼルシャフト | Vegf受容体阻害剤と化学療法剤の組み合わせ |
US7552093B2 (en) * | 2003-12-04 | 2009-06-23 | Black Duck Software, Inc. | Resolving license dependencies for aggregations of legally-protectable content |
US20070134670A1 (en) | 2003-12-12 | 2007-06-14 | Bayer Pharmaceuticals Corporation | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
MXPA06012394A (es) * | 2004-04-30 | 2007-01-31 | Bayer Pharmaceuticals Corp | Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer. |
MXPA06015267A (es) | 2004-06-22 | 2007-03-15 | Pfizer Prod Inc | Antagonistas diazabiciclicos del receptor histamina-3. |
ES2306216T3 (es) | 2004-08-27 | 2008-11-01 | Bayer Pharmaceuticals Corporation | Composiciones farmaceuticas en forma de dispersiones solidas para el tratamiento de cancer. |
MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
US8877933B2 (en) | 2004-09-29 | 2014-11-04 | Bayer Intellectual Property Gmbh | Thermodynamically stable form of a tosylate salt |
NZ554119A (en) | 2004-09-29 | 2010-07-30 | Bayer Schering Pharma Ag | Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide |
CN104688697A (zh) | 2005-03-07 | 2015-06-10 | 拜尔健康护理有限责任公司 | 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物 |
AU2006251428A1 (en) * | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Combination therapy comprising diaryl ureas for treating diseases |
BRPI0610048A2 (pt) | 2005-05-27 | 2010-05-25 | Bayer Healthcare Ag | terapia de combinação que compreende um composto de diaril uréia e uma pi3, akt quinase ou inibidores de mtor (rapamicinas) para o tratamento de cáncer |
US20080305962A1 (en) | 2005-07-29 | 2008-12-11 | Ralph Markus Wirtz | Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies |
JP2009512860A (ja) | 2005-10-21 | 2009-03-26 | バイエル ヘルスケア エルエルシー | がんの予測及び予後の検査方法、並びにがん治療のモニタリング |
JP2009513707A (ja) * | 2005-10-31 | 2009-04-02 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | ジアリールウレア及び併用剤 |
EP1954272A2 (en) * | 2005-10-31 | 2008-08-13 | Bayer Pharmaceuticals Corporation | Treatment of cancer with sorafenib |
US8329408B2 (en) * | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
CA2626054A1 (en) * | 2005-11-02 | 2007-05-18 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
EP1943521A4 (en) | 2005-11-02 | 2009-12-30 | Bayer Healthcare Llc | METHOD FOR PREDICTING AND FORECASTING CANCER AND MONITORING CANCER THERAPY |
DK1948176T3 (da) | 2005-11-10 | 2011-04-18 | Bayer Schering Pharma Ag | Diarylurinstoffer til behandling af pulmonær hypertension |
EP1963849A2 (en) * | 2005-11-14 | 2008-09-03 | Bayer Healthcare, LLC | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
WO2007059155A1 (en) | 2005-11-14 | 2007-05-24 | Bayer Pharmaceuticals Corporation | Treatment of cancers having resistance to chemotherapeutic agents |
CA2629863A1 (en) | 2005-11-14 | 2007-05-24 | Scott Wilhelm | Use of sorafenib for the treatment of cancers with acquired resistance to kit inhibitors |
EP2044053A2 (en) | 2005-12-01 | 2009-04-08 | Bayer Healthcare, LLC | Urea compounds useful in the treatment of cancer |
US20090227637A1 (en) * | 2005-12-15 | 2009-09-10 | Olaf Weber | Diaryl ureas for treating virus infections |
US8101773B2 (en) | 2006-12-20 | 2012-01-24 | Bayer Healthcare Llc | Hydroxy methyl phenyl pyrazolyl urea compounds useful in the treatment of cancer |
JP5885012B2 (ja) | 2007-01-19 | 2016-03-15 | バイエル・ヘルスケア・エルエルシーBayer HealthCareLLC | Kit阻害剤に対して獲得した抵抗性を有する癌の処置 |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
EP2726057A1 (en) | 2011-06-28 | 2014-05-07 | Bayer HealthCare LLC | Topical ophthalmological pharmaceutical composition containing sorafenib |
EP2559431A1 (en) | 2011-08-17 | 2013-02-20 | Ratiopharm GmbH | Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide |
-
2006
- 2006-02-22 CN CN201510055041.5A patent/CN104688697A/zh active Pending
- 2006-02-22 CN CN200680007187.1A patent/CN101132779B/zh not_active Ceased
- 2006-02-22 PL PL06707141T patent/PL1868579T3/pl unknown
- 2006-02-22 WO PCT/EP2006/001574 patent/WO2006094626A1/en active Application Filing
- 2006-02-22 DK DK06707141.5T patent/DK1868579T3/da active
- 2006-02-22 PT PT06707141T patent/PT1868579E/pt unknown
- 2006-02-22 BR BRPI0608840A patent/BRPI0608840B8/pt active IP Right Grant
- 2006-02-22 MX MX2007010856A patent/MX2007010856A/es active IP Right Grant
- 2006-02-22 AT AT06707141T patent/ATE482693T1/de active
- 2006-02-22 US US11/885,930 patent/US9737488B2/en active Active
- 2006-02-22 DE DE602006017188T patent/DE602006017188D1/de active Active
- 2006-02-22 ES ES06707141T patent/ES2351612T3/es active Active
- 2006-02-22 UA UAA200711110A patent/UA93673C2/ru unknown
- 2006-02-22 JP JP2008500066A patent/JP5304241B2/ja active Active
- 2006-02-22 SG SG201001549-3A patent/SG160364A1/en unknown
- 2006-02-22 SI SI200630863T patent/SI1868579T1/sl unknown
- 2006-02-22 EP EP06707141A patent/EP1868579B1/en not_active Revoked
- 2006-02-22 NZ NZ561178A patent/NZ561178A/en unknown
- 2006-02-22 AU AU2006222365A patent/AU2006222365B2/en active Active
- 2006-02-22 CA CA2601955A patent/CA2601955C/en active Active
- 2006-02-22 KR KR1020077020370A patent/KR101335932B1/ko active IP Right Review Request
- 2006-02-27 GT GT200600096A patent/GT200600096A/es unknown
- 2006-03-03 MY MYPI20060919A patent/MY162319A/en unknown
- 2006-03-03 AR AR20060100820A patent/AR054234A1/es not_active Application Discontinuation
- 2006-03-03 DO DO2006000057A patent/DOP2006000057A/es unknown
- 2006-03-06 TW TW095107345A patent/TWI324928B/zh active
- 2006-03-06 UY UY29410A patent/UY29410A1/es not_active Application Discontinuation
- 2006-03-06 PE PE2006000250A patent/PE20061345A1/es active IP Right Grant
- 2006-03-07 HN HN2006009702A patent/HN2006009702A/es unknown
-
2007
- 2007-08-27 IL IL185517A patent/IL185517A/en active IP Right Grant
- 2007-08-28 CR CR9348A patent/CR9348A/es unknown
- 2007-08-30 CU CU20070203A patent/CU23821A3/es active IP Right Grant
- 2007-09-05 ZA ZA200707638A patent/ZA200707638B/xx unknown
- 2007-09-06 TN TNP2007000341A patent/TNSN07341A1/en unknown
- 2007-10-02 MA MA30267A patent/MA29378B1/fr unknown
- 2007-10-05 NO NO20075042A patent/NO343834B1/no unknown
-
2008
- 2008-08-19 HK HK08109248.3A patent/HK1118019A1/zh unknown
-
2010
- 2010-12-06 HR HR20100674T patent/HRP20100674T1/hr unknown
- 2010-12-10 CY CY20101101138T patent/CY1111065T1/el unknown
-
2015
- 2015-10-22 HK HK15110355.1A patent/HK1209620A1/xx unknown
-
2017
- 2017-08-22 US US15/683,210 patent/US20180036249A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100674T1 (hr) | Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka | |
EP2777696B1 (en) | Preparation of stable pharmaceutical dosage forms | |
JP2021038242A (ja) | ルカパリブの高投与力価錠剤 | |
HRP20192064T1 (hr) | Formulacije apiksabana | |
HRP20161262T1 (hr) | Tablete ulipristal acetata | |
ITMI20001450A1 (it) | Nuova composizione farmaceutica | |
ZA200508361B (en) | Orally disintegrating tablets | |
JP2016536285A (ja) | アムロジピン及びバルサルタンを含む安定な医薬組成物 | |
JPS6241646B2 (hr) | ||
US20140335176A1 (en) | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing | |
JP6009967B2 (ja) | 固形製剤 | |
JP2017122056A (ja) | 医薬含有造粒物の製造方法 | |
JP2012529431A (ja) | トロンビン受容体アンタゴニストおよびクロピドグレルの固定用量錠剤 | |
JP6308938B2 (ja) | 粒状物を製造する方法 | |
JP2011246428A (ja) | 口腔内崩壊型医薬品及びその製造方法 | |
JP2007332074A (ja) | 口腔内速崩壊錠およびその製造方法 | |
CN102349915A (zh) | 一种氨酚咖敏维c制剂及其制备方法 | |
JP2017520619A (ja) | セリチニブ製剤 | |
JP2004522780A5 (hr) | ||
HRP20191669T1 (hr) | Farmaceutski sastav koji sadrži polimer koji veže fosfate | |
CA3122196A1 (en) | Process for the preparation of easy-to-take tablets containing dry extract of ginkgo biloba leaves | |
JP2005502729A (ja) | 植物抽出物から錠剤を製造するための方法 | |
CA3048968A1 (en) | Oral pharmaceutical composition of lurasidone and preparation thereof | |
ES2954286T3 (es) | Composiciones de piridostigmina de liberación sostenida | |
HRP20221073T1 (hr) | Postupak pripreme postojanih formulacija mesalazina |